What'sGoing On With AbCellera Biologics Stock On Tuesday?
AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
Stocks · News reference
Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday
BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained 16.4%, AQST gained 15.4%, STDN rose 13.7%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday
Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
8-K filing — AbCellera Biologics Inc. (ABCL)
Filed: 2026-08-13 AccNo: 0001193125-26-349353 Size: 616 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
AbCellera Prices Oversubscribed $200.0M Offering Of 17,435,897 Common Shares At $9.75 Per Share
Joby and Archer Aviation Are Falling Just as Air Taxis Near Reality
Here's why Joby and Archer Aviation stocks are falling as the evtol dream nears the commercialization stage later this year.
Prediction: Here's What a $5,000 Investment in Joby Aviation Will Be Worth in 3 Years
Joby Aviation, an eVTOL aircraft developer, has underperformed since going public but could see significant growth once the FAA certifies its commercial flights. The company's S4 aircraft offers advantages over competitors like Archer Aviation, with backing from Toyota, Delta Air Lines, and Uber. Analysts project revenue could grow from $53M in 2025 to $435M by 2028, potentially doubling the company's market cap to $14B over three years, though the stock remains highly speculative with ongoing cash burn and shareholder dilution.